포스포디에스테라제 5 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 7.2%의 연평균 성장률(CAGR)로 62억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 경구 및 비침습적 치료에 대한 수요 증가, 성 건강 치료에 대한 원격의료 채택 확대, 맞춤형 의료에 대한 관심 증가, 남성 불임 치료에 대한 관심 증가 등이 성장의 원동력이 될 것으로 예상됩니다. 이 기간의 주요 동향으로는 병용요법 개발, 정제 병용요법과의 통합, 표적 치료제의 혁신, 비약물 대체제의 출현, PDE5 표적 치료제 개발에서 인공지능의 통합 등이 있습니다.
발기부전 유병률의 증가는 포스포디에스테라제 5 억제제 시장의 성장을 견인할 것으로 예상됩니다. 발기부전(ED)은 만족스러운 성행위를 하기에 충분한 발기를 지속적으로 달성하거나 유지하지 못하는 것으로 정의되며, 발기부전 유병률 증가는 호르몬 불균형, 특히 성기능과 성과에 영향을 미치는 테스토스테론 수치 감소가 주요 원인으로 작용합니다. 포스포디에스테라제 5 억제제는 음경으로의 혈류를 촉진하여 남성이 성적 자극에 반응하여 발기하고 이를 유지할 수 있도록함으로써 발기부전 치료에 도움을 줄 수 있습니다. 예를 들어, 2024년 12월 영국 약국 LloydsPharmacy Online Doctor는 2023년 NHS가 2023년 9월부터 2024년 8월까지 약 350만 건의 비아그라 처방전을 발행하여 약 2,550만 정을 유통시켰다고 보고했습니다. 이러한 발기부전의 확산은 포스포디에스테라제 5 억제제 시장 확대에 박차를 가하고 있습니다.
연구 및 임상시험의 증가는 포스포디에스테라제 5 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 임상시험은 새로운 치료법, 의약품, 의료기기의 안전성, 유효성, 잠재적 부작용을 평가하기 위해 사람을 대상으로 하는 연구입니다. 임상시험의 증가는 주로 진화하는 의료 수요에 대응하고 환자 결과를 개선하기 위한 새로운 치료법에 대한 수요로 인해 발생합니다. 포스포디에스테라제 5 억제제는 발기부전 및 폐동맥 고혈압과 같은 질환에 대한 치료 효과 평가를 개선함으로써 임상시험 과정을 지원하고 보다 타겟팅된 치료법 개발을 지원합니다. 예를 들어, 영국 제약산업협회(ABPI)가 2023년 11월에 발표한 보고서에 따르면, 영국에서 매년 시작되는 산업 임상시험의 총 수는 2021년 394건에서 2022년 411건으로 4.3% 증가했다고 합니다. 그 결과, 조사 및 임상 검사의 증가는 포스포디에스테라제 5 억제제 시장을 발전시킬 것으로 예상됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 포스포디에스테라제 5 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 포스포디에스테라제 5 억제제 시장 : 성장률 분석
- 세계의 포스포디에스테라제 5 억제제 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 포스포디에스테라제 5 억제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 포스포디에스테라제 5 억제제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 포스포디에스테라제 5 억제제 시장 : 약물 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- Sildenafil
- Tadalafil
- Vardenafil
- Avanafil
- 기타 약물 유형
- 세계의 포스포디에스테라제 5 억제제 시장 : 제형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 정제
- 주사제
- 국소제
- 세계의 포스포디에스테라제 5 억제제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 발기부전
- 폐동맥 고혈압
- 양성 전립선 비대증
- 기타
- 세계의 포스포디에스테라제 5 억제제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 소매 약국
- 온라인 약국
- 병원 약국
- 세계의 포스포디에스테라제 5 억제제 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원
- 전문 클리닉
- 재택 케어
- 세계의 포스포디에스테라제 5 억제제 시장, Sildenafil 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 제네릭 Sildenafil
- 브랜드 Sildenafil
- 세계의 포스포디에스테라제 5 억제제 시장, Tadalafil 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 제네릭 Tadalafil
- 브랜드 Tadalafil
- 세계의 포스포디에스테라제 5 억제제 시장, Vardenafil 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 제네릭 Vardenafil
- 브랜드 Vardenafil
- 세계의 포스포디에스테라제 5 억제제 시장, Avanafil 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 제네릭 Avanafil
- 브랜드 Avanafil
- 세계의 포스포디에스테라제 5 억제제 시장, 기타 약물 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- Udenafil
- Lodenafil
- Mirodenafil
제7장 지역별·국가별 분석
- 세계의 포스포디에스테라제 5 억제제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 포스포디에스테라제 5 억제제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 포스포디에스테라제 5 억제제 시장 : 경쟁 구도
- 포스포디에스테라제 5 억제제 시장 : 기업 개요
- Pfizer Inc.
- Johnson And Johnson
- Merck And Co. Inc.
- Bayer AG
- GlaxoSmithKline plc
제31장 기타 주요 기업과 혁신적 기업
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc
- Aurobindo Pharma Ltd
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Vectura Group
- Vivus Inc
- Seoul Pharma
- Auxilium Pharmaceuticals
- Metuchen Pharma
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 전략
- 포스포디에스테라제 5 억제제 시장, 2029년 : 새로운 기회를 제공하는 국가
- 포스포디에스테라제 5 억제제 시장, 2029년 : 새로운 기회를 제공하는 부문
- 포스포디에스테라제 5 억제제 시장, 2029년 : 성장 전략
제36장 부록
ksm
A phosphodiesterase 5 (PDE5) inhibitor is a type of drug that blocks the enzyme PDE5, which normally breaks down cyclic guanosine monophosphate (cGMP). This molecule plays a key role in relaxing smooth muscle tissue and increasing blood flow. PDE5 inhibitors are commonly used to treat erectile dysfunction and pulmonary arterial hypertension by improving blood flow in targeted areas.
The main types of phosphodiesterase 5 inhibitors include sildenafil, tadalafil, vardenafil, avanafil, and others. Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension by relaxing blood vessels and boosting blood flow to specific areas. These medications come in various forms, such as tablets, injectables, and topical applications. They are used to treat conditions like erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and other related disorders. These drugs are distributed through retail pharmacies, online pharmacies, and hospital pharmacies, and are used in hospitals, specialty clinics, and home care settings.
The phosphodiesterase 5 inhibitor market research report is one of a series of new reports from The Business Research Company that provides phosphodiesterase 5 inhibitor market statistics, including the phosphodiesterase 5 inhibitor industry's global market size, regional shares, competitors with the phosphodiesterase 5 inhibitor market share, detailed phosphodiesterase 5 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the phosphodiesterase 5 inhibitor market. This phosphodiesterase 5 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The phosphodiesterase 5 inhibitor market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of erectile dysfunction, heightened awareness about sexual health, a growing geriatric population, a rising preference for non-invasive treatment options, and an increase in lifestyle-related diseases.
The phosphodiesterase 5 inhibitor market size is expected to see strong growth in the next few years. It will grow to $6.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. In the forecast period, growth is expected to be driven by a rising demand for oral, non-invasive therapeutics, greater adoption of telemedicine for sexual health treatment, an increasing focus on personalized medicine, and a growing emphasis on male fertility treatments. Key trends during this period include the development of combination therapies, integration with combination pill regimens, innovation in targeted therapies, the emergence of non-pharmaceutical alternatives, and the integration of artificial intelligence in PDE5-targeted drug discovery.
The growing prevalence of erectile dysfunction is expected to drive the growth of the phosphodiesterase 5 inhibitor market. Erectile dysfunction (ED) is defined by the consistent inability to achieve or maintain an erection adequate for satisfactory sexual performance. The rising prevalence of ED is largely attributed to hormonal imbalances, particularly low testosterone levels, which affect sexual function and performance. Phosphodiesterase 5 inhibitors help treat erectile dysfunction by enhancing blood flow to the penis, allowing men to achieve and sustain an erection in response to sexual stimulation. For example, in December 2024, LloydsPharmacy Online Doctor, a UK-based pharmacy, reported that in 2023, the NHS issued nearly 3.5 million prescriptions for Viagra, leading to the distribution of about 25.5 million pills between September 2023 and August 2024. This growing prevalence of erectile dysfunction is fueling the expansion of the phosphodiesterase 5 inhibitor market.
The rise in research and clinical trials is also expected to boost the growth of the phosphodiesterase 5 inhibitor market. Clinical trials are research studies involving human participants designed to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in clinical trials is primarily driven by the demand for new treatments to address evolving healthcare needs and enhance patient outcomes. Phosphodiesterase 5 inhibitors support the clinical trial process by improving the evaluation of therapeutic efficacy for conditions like erectile dysfunction and pulmonary hypertension, thus aiding the development of more targeted treatments. For instance, a report from the Association of the British Pharmaceutical Industry (ABPI) in November 2023 noted that the total number of industry clinical trials initiated annually in the UK rose by 4.3%, from 394 trials in 2021 to 411 in 2022. As a result, the growth in research and clinical trials is expected to propel the phosphodiesterase 5 inhibitor market forward.
Major companies in the phosphodiesterase 5 inhibitor market are focusing on developing innovative products, such as generic versions of Stendra. These generics contain the same active ingredient, avanafil, and help treat erectile dysfunction by inhibiting the PDE5 enzyme, which enhances blood flow to the penis. In October 2024, Camber Pharmaceuticals, Inc., a US-based pharmaceutical company, launched Avanafil tablets in 50 mg, 100 mg, and 200 mg strengths, each available in 30-count bottles. Avanafil works by improving blood flow to the penis during sexual stimulation, with effects typically felt within 15 minutes and lasting for more than six hours.
Major players in the phosphodiesterase 5 inhibitor market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, GlaxoSmithKline plc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Apotex Inc, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd., Cipla Ltd, Lupin Limited, Torrent Pharmaceuticals Ltd., Vectura Group, Vivus Inc, Seoul Pharma, Auxilium Pharmaceuticals, Metuchen Pharma.
North America was the largest region in the phosphodiesterase 5 inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphodiesterase 5 inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the phosphodiesterase 5 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The phosphodiesterase 5 inhibitor market consists of sales of products including sildenafil, tadalafil, vardenafil, avanafil, and lodenafil. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Phosphodiesterase 5 Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on phosphodiesterase 5 inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for phosphodiesterase 5 inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phosphodiesterase 5 inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Sildenafil; Tadalafil; Vardenafil; Avanafil; Other Drug Types
- 2) By Dosage Form: Tablets; Injectables; Topical Applications
- 3) By Application: Erectile Dysfunction; Pulmonary Arterial Hypertension; Benign Prostatic Hyperplasia; Other Applications
- 4) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospital Pharmacies
- 5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
- Subsegments:
- 1) By Sildenafil: Generic Sildenafil; Branded Sildenafil
- 2) By Tadalafil: Generic Tadalafil; Branded Tadalafil
- 3) By Vardenafil: Generic Vardenafil; Branded Vardenafil
- 4) By AvanafilP: Generic Avanafil; Branded Avanafil
- 5) By Other Drug Types: Udenafil; Lodenafil; Mirodenafil
- Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck And Co. Inc.; Bayer AG; GlaxoSmithKline plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Phosphodiesterase 5 Inhibitor Market Characteristics
3. Phosphodiesterase 5 Inhibitor Market Trends And Strategies
4. Phosphodiesterase 5 Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Phosphodiesterase 5 Inhibitor Growth Analysis And Strategic Analysis Framework
- 5.1. Global Phosphodiesterase 5 Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Phosphodiesterase 5 Inhibitor Market Growth Rate Analysis
- 5.4. Global Phosphodiesterase 5 Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Phosphodiesterase 5 Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Phosphodiesterase 5 Inhibitor Total Addressable Market (TAM)
6. Phosphodiesterase 5 Inhibitor Market Segmentation
- 6.1. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sildenafil
- Tadalafil
- Vardenafil
- Avanafil
- Other Drug Types
- 6.2. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablets
- Injectables
- Topical Applications
- 6.3. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Erectile Dysfunction
- Pulmonary Arterial Hypertension
- Benign Prostatic Hyperplasia
- Other Applications
- 6.4. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- 6.5. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare Settings
- 6.6. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Sildenafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Sildenafil
- Branded Sildenafil
- 6.7. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Tadalafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Tadalafil
- Branded Tadalafil
- 6.8. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Vardenafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Vardenafil
- Branded Vardenafil
- 6.9. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Avanafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Generic Avanafil
- Branded Avanafil
- 6.10. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Udenafil
- Lodenafil
- Mirodenafil
7. Phosphodiesterase 5 Inhibitor Market Regional And Country Analysis
- 7.1. Global Phosphodiesterase 5 Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Phosphodiesterase 5 Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Phosphodiesterase 5 Inhibitor Market
- 8.1. Asia-Pacific Phosphodiesterase 5 Inhibitor Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Phosphodiesterase 5 Inhibitor Market
- 9.1. China Phosphodiesterase 5 Inhibitor Market Overview
- 9.2. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Phosphodiesterase 5 Inhibitor Market
- 10.1. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Phosphodiesterase 5 Inhibitor Market
- 11.1. Japan Phosphodiesterase 5 Inhibitor Market Overview
- 11.2. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Phosphodiesterase 5 Inhibitor Market
- 12.1. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Phosphodiesterase 5 Inhibitor Market
- 13.1. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Phosphodiesterase 5 Inhibitor Market
- 14.1. South Korea Phosphodiesterase 5 Inhibitor Market Overview
- 14.2. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Phosphodiesterase 5 Inhibitor Market
- 15.1. Western Europe Phosphodiesterase 5 Inhibitor Market Overview
- 15.2. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Phosphodiesterase 5 Inhibitor Market
- 16.1. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Phosphodiesterase 5 Inhibitor Market
- 17.1. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Phosphodiesterase 5 Inhibitor Market
- 18.1. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Phosphodiesterase 5 Inhibitor Market
- 19.1. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Phosphodiesterase 5 Inhibitor Market
- 20.1. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Phosphodiesterase 5 Inhibitor Market
- 21.1. Eastern Europe Phosphodiesterase 5 Inhibitor Market Overview
- 21.2. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Phosphodiesterase 5 Inhibitor Market
- 22.1. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Phosphodiesterase 5 Inhibitor Market
- 23.1. North America Phosphodiesterase 5 Inhibitor Market Overview
- 23.2. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Phosphodiesterase 5 Inhibitor Market
- 24.1. USA Phosphodiesterase 5 Inhibitor Market Overview
- 24.2. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Phosphodiesterase 5 Inhibitor Market
- 25.1. Canada Phosphodiesterase 5 Inhibitor Market Overview
- 25.2. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Phosphodiesterase 5 Inhibitor Market
- 26.1. South America Phosphodiesterase 5 Inhibitor Market Overview
- 26.2. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Phosphodiesterase 5 Inhibitor Market
- 27.1. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Phosphodiesterase 5 Inhibitor Market
- 28.1. Middle East Phosphodiesterase 5 Inhibitor Market Overview
- 28.2. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Phosphodiesterase 5 Inhibitor Market
- 29.1. Africa Phosphodiesterase 5 Inhibitor Market Overview
- 29.2. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Phosphodiesterase 5 Inhibitor Market Competitive Landscape And Company Profiles
- 30.1. Phosphodiesterase 5 Inhibitor Market Competitive Landscape
- 30.2. Phosphodiesterase 5 Inhibitor Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
31. Phosphodiesterase 5 Inhibitor Market Other Major And Innovative Companies
- 31.1. Eli Lilly And Company
- 31.2. Teva Pharmaceutical Industries Ltd.
- 31.3. Boehringer Ingelheim
- 31.4. Sun Pharmaceutical Industries Ltd.
- 31.5. Apotex Inc
- 31.6. Aurobindo Pharma Ltd
- 31.7. Dr. Reddy's Laboratories Ltd.
- 31.8. Cipla Ltd
- 31.9. Lupin Limited
- 31.10. Torrent Pharmaceuticals Ltd.
- 31.11. Vectura Group
- 31.12. Vivus Inc
- 31.13. Seoul Pharma
- 31.14. Auxilium Pharmaceuticals
- 31.15. Metuchen Pharma
32. Global Phosphodiesterase 5 Inhibitor Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Phosphodiesterase 5 Inhibitor Market
34. Recent Developments In The Phosphodiesterase 5 Inhibitor Market
35. Phosphodiesterase 5 Inhibitor Market High Potential Countries, Segments and Strategies
- 35.1 Phosphodiesterase 5 Inhibitor Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Phosphodiesterase 5 Inhibitor Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Phosphodiesterase 5 Inhibitor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
